Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459771 | 0.85 | GRM2 (0.40) | GRM2MMP2MMP9MMP3NAAA | |
| SCHEMBL4445297 | 0.82 | GRM2 (0.38) | GRM2MMP2MMP9MMP3NAAA | |
| SCHEMBL4472190 | 0.81 | GRM2 (0.37) | GRM2MMP2MMP9MMP3 | |
| SCHEMBL4447348 | 0.74 | GRM2 (0.42) | GRM2MMP2MMP9MMP3CES2 | |
| SCHEMBL4453549 | 0.71 | SMN1; SMN2 (0.39) | GRM2SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6427016 | 0.62 | PLA2G7 (0.36) | GRM2SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL4452493 | 0.61 | MMP2 (0.41) | GRM2MMP2MMP9MMP3L3MBTL1 | |
| SCHEMBL4460824 | 0.60 | GAA (0.42) | GRM2MMP2MMP9MMP3L3MBTL1 | |
| SCHEMBL4458256 | 0.59 | IDH1 (0.39) | SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL4450103 | 0.58 | GAA (0.40) | GRM2MMP2MMP9MMP3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885SMN1; SMN2 902/4885MMP2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.